目的 开展紫杉醇所致眼部损伤药学干预,探讨其发生机制,并提出防治建议。方法 分析紫杉醇眼部损伤与剂型的关系,以紫杉醇化疗致眼部损伤个案为药学干预对象,监护患者眼部损伤不良反应,记录不同剂型紫杉醇致眼部损伤情况,探讨减轻ADR的防治实施。结果 紫杉醇导致眼部损伤存在剂量相关性,紫杉醇脂质体替代紫杉醇注射液不能减轻眼部损伤,白蛋白结合型紫杉醇有明确的眼损伤,避免特殊人群使用。结论 充分认识紫杉醇致眼部损伤机制及防治措施,开展有效的药学干预,可使患者最大获益。

Objective To carry out the pharmaceutical intervention of eye damage caused by paclitaxel, and to explore the pathogenetic mechanism, and to offer precautionary and control suggestions. Methods To analyze the relationship between eye damage and dosage form of paclitaxel. A case of eye damage induced by chemotherapy with paclitaxel was used as pharmaceutical intervention. The adverse drug reaction (ADR) of eye damage was monitored, and eye damage induced by paclitaxel with different dosage forms was recorded, and to explore the precautionary and control implementation of reducing ADR. Results Eye damage caused by paclitaxel was dose-relatived. Paclitaxel Liposome instead of Paclitaxel Injection could not induce the eye damage. Abraxane had specific eye damage, and it should be avoided using for special crowd. Conclusion Fully understanding the mechanism and prevention measures of eye damage caused by paclitaxel and carrying out the effective pharmaceutical intervention can make the biggest benefit for patients.